Past, present, and future policy considerations regarding meningococcal vaccination in the United States.

IF 5.5 3区医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-09-11 DOI:10.1080/14760584.2024.2397705

Diana E Clements, Tosin Olaiya, Cindy Burman, Oscar Herrera-Restrepo, Woo-Yun Sohn, Temi Folaranmi, Victoria Abbing-Karahagopian, Gary S Marshall, James H Conway

{"title":"Past, present, and future policy considerations regarding meningococcal vaccination in the United States.","authors":"Diana E Clements, Tosin Olaiya, Cindy Burman, Oscar Herrera-Restrepo, Woo-Yun Sohn, Temi Folaranmi, Victoria Abbing-Karahagopian, Gary S Marshall, James H Conway","doi":"10.1080/14760584.2024.2397705","DOIUrl":null,"url":null,"abstract":"Introduction: In 2005, the United States Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y (MenACWY) for all 11-12-year-olds, as well as 2-10-year-olds at high risk. In 2010, a booster dose was recommended for all 16-year-olds, as well as for high-risk patients every 3-5 years. In 2015, optional (as opposed to routine) vaccination against meningococcal serogroup B (MenB) at the preferred age of 16-18 years was recommended (Category B, later changed to shared clinical decision-making). In 2023, a vaccine (MenABCWY) against the five serogroups primarily responsible for IMD in the U.S. became available.Areas covered: This review summarizes the evolution of public policy that led to each milestone vaccine recommendation, reviews epidemiologic data published following the recommendations, and discusses the current state of meningococcal immunization policy.Expert opinion: The use of MenABCWY has the potential to consolidate policy, improve coverage rates for the five serogroups, address disparities in vaccination coverage, and simplify vaccine delivery.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2397705","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In 2005, the United States Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y (MenACWY) for all 11-12-year-olds, as well as 2-10-year-olds at high risk. In 2010, a booster dose was recommended for all 16-year-olds, as well as for high-risk patients every 3-5 years. In 2015, optional (as opposed to routine) vaccination against meningococcal serogroup B (MenB) at the preferred age of 16-18 years was recommended (Category B, later changed to shared clinical decision-making). In 2023, a vaccine (MenABCWY) against the five serogroups primarily responsible for IMD in the U.S. became available.

Areas covered: This review summarizes the evolution of public policy that led to each milestone vaccine recommendation, reviews epidemiologic data published following the recommendations, and discusses the current state of meningococcal immunization policy.

Expert opinion: The use of MenABCWY has the potential to consolidate policy, improve coverage rates for the five serogroups, address disparities in vaccination coverage, and simplify vaccine delivery.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

美国脑膜炎球菌疫苗接种的过去、现在和未来政策考虑。

导言：2005 年，美国免疫实践咨询委员会 (ACIP) 建议为所有 11-12 岁的青少年以及 2-10 岁的高危人群常规接种由 A、C、W 和 Y 血清群 (MenACWY) 引起的侵袭性脑膜炎球菌病 (IMD) 疫苗。2010 年，建议所有 16 岁儿童以及高危患者每 3-5 年加强一次疫苗接种。2015 年，建议在首选年龄 16-18 岁接种脑膜炎球菌血清 B 群 (MenB) 疫苗（B 类，后改为共同临床决策）。2023 年，针对 5 个主要导致美国 IMD 的血清群的疫苗（MenABCWY）上市：本综述总结了促成每项里程碑式疫苗建议的公共政策演变，回顾了建议提出后公布的流行病学数据，并讨论了脑膜炎球菌免疫接种政策的现状：专家意见：使用 MenABCWY 有可能整合政策，提高 5 个血清群的覆盖率，解决疫苗接种覆盖率不均的问题，并简化疫苗接种过程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.